Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Companyâ€™s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/07/26	US$0.2613	-2.02%	4,535
29/07/26	US$0.2667	+1.02%	67,383
28/07/26	US$0.2640	+6.97%	485,997
27/07/26	US$0.2468	+7.30%	69,306
24/07/26	US$0.2300	-6.92%	35,256

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Other stock markets 14:32:43 30/07/2026 BST			5-day change	1st Jan Change
0.2613 ^USD	-2.02%		+5.75%	-63.31%

06-15	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Scinai Immunotherapeutics Ltd. Appoints Eilon Elmalem as Site Head of Yavne Cdmo Facility, Effective June 14, 2026	CI

Market Cap	1.06M 928K 866K 795K 1.49M 101M 1.52M 10.27M 4.02M 50.06M 3.97M 3.88M 173M	P/E 2024 *	-	P/E 2025	-0.2x
Enterprise Value	1.66M 1.46M 1.36M 1.25M 2.34M 159M 2.4M 16.17M 6.32M 78.78M 6.24M 6.1M 272M	EV / Sales 2024	4,521,684x	EV / Sales 2025	2,346,088x
Free-Float	0.36%	Yield 2024 *	-	Yield 2025	-

06-15	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Scinai Immunotherapeutics Ltd. Appoints Eilon Elmalem as Site Head of Yavne Cdmo Facility, Effective June 14, 2026	CI
04-27	Scinai Immunotherapeutics Ltd. announced that it has received $2.5 million in funding	CI
04-23	Scinai Immunotherapeutics Ltd. announced that it expects to receive $2.5 million in funding	CI
04-06	Scinai completes strategic reorganization to establish dedicated CDMO platform and lean R&D structure; outlines 2026 priorities	RE
04-06	Scinai Immunotherapeutics Leverages Strategic Collaboration with Recipharm to Build Integrated Lifecycle CDMO Platform	CI
04-01	Scinai reports full-year 2025 results, with cdmo revenues doubling and strategic expansion through Recipharm collaboration	RE
04-01	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Scinai Immunotherapeutics Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-16	Scinai Immunotherapeutics receives Nasdaq notification regarding minimum bid price	RE
03-02	Scinai signs second amendment to Pincell option agreement and submits revised EUR12 million non-dilutive Feng application to advance Pc111 through human proof of concept	RE
02-25	Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform	CI
02-17	Scinai Immunotherapeutics Ltd. acquired Recipharm Israel Ltd. from Recipharm AB.	CI

05-18	Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe	AQ
04-27	Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing	AQ
03-19	Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026	PR
03-16	Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price	PR
03-02	Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept	PR

Scinai Immunotherapeutics Ltd. Share Price

Stocks

SCNI

US09073Q3039

Biotechnology & Medical Research

Valuation: Scinai Immunotherapeutics Ltd.

Chart: Scinai Immunotherapeutics Ltd.

Latest news : Scinai Immunotherapeutics Ltd.

Analysts' recommendations: Scinai Immunotherapeutics Ltd.

Press Releases: Scinai Immunotherapeutics Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Scinai Immunotherapeutics Ltd.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-2.02%
1 week	+5.75%
Current month	+3.44%
1 month	+3.44%
3 months	-64.69%
6 months	-73.34%
Current year	-63.31%

1 week	0.23	0.29
1 month	0.21	0.29
Current year	0.21	1.12
1 year	0.21	1.97
3 years	0.21	14.2
5 years	0.21	349
10 years	0.21	6,199.99

Manager	Title	Age	Since
Amir Reichman CEO	Chief Executive Officer	51	01/03/2021
Uri Ben-Or DFI	Director of Finance/CFO	54	31/12/2006
Dalit Fischer CTO	Chief Tech/Sci/R&D Officer	-	31/12/2021

Director	Title	Age	Since
Adi Raviv BRD	Director/Board Member	71	23/03/2020
Samuel Moed BRD	Director/Board Member	64	23/03/2020
Mark Germain CHM	Chairman	77	29/09/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/01/23	Jay Green	Other	Director	1,200,000	0.1606%
01/01/23	Samuel Moed	Other	Director	4,000,000	0.5354%
01/01/23	Uri Ben-Or	Other	Chief Financial Officer	880,000	0.1178%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCINAI IMMUNOTHERAPEUTICS LTD.	-2.02%	+5.75%	-83.77%	-98.04%	1.06M
LONZA GROUP AG	+0.31%	+6.42%	+0.49%	+14.21%	48.95B
IQVIA HOLDINGS INC.	-3.79%	+15.93%	+25.48%	+7.41%	40.75B
REVOLUTION MEDICINES, INC.	+3.80%	-2.57%	+396.83%	+600.57%	38.46B
BEONE MEDICINES AG	-1.57%	-0.75%	+8.13%	+51.40%	36.38B
CELLTRION, INC.	+1.47%	+5.82%	+5.76%	+43.52%	28.45B
ASCENDIS PHARMA A/S	-0.72%	-0.79%	-	-	16.62B
MEDPACE HOLDINGS, INC.	-1.92%	-4.82%	+31.71%	+127.75%	16.33B
ICON PUBLIC LIMITED COMPANY	-6.73%	-1.98%	-8.01%	-33.59%	13.65B
EUROFINS SCIENTIFIC SE	0.00%	+3.81%	+3.87%	+9.68%	13.56B
Average	-1.14%	+5.74%	+42.28%	+80.32%	25.31B
Weighted average by Cap.	-0.61%	+6.92%	+72.91%	+122.46%

	2024	2025
Net sales	0.66 0.58 0.54 0.5 0.93 63.03 0.95 6.4 2.5 31.19 2.47 2.42 107.82	1.31 1.15 1.08 0.99 1.85 125.57 1.89 12.75 4.99 62.14 4.92 4.82 214.81
Net income	4.8M 4.21M 3.93M 3.61M 6.76M 459M 6.92M 46.65M 18.24M 227M 18.01M 17.62M 786M	-8.31M -7.3M -6.81M -6.25M -11.71M -796M -11.99M -80.79M -31.6M -394M -31.19M -30.51M -1.36B
Net Debt	122K 107K 100K 91.83K 172K 11.69M 176K 1.19M 464K 5.78M 458K 448K 19.99M	606K 532K 497K 456K 854K 58.04M 875K 5.89M 2.3M 28.72M 2.28M 2.23M 99.29M